Divi's Labs Q1 FY27 Consolidated Income at ₹3,144 Cr, PAT ₹902 Cr
Divi's Laboratories reported Q1 FY27 consolidated income of ₹3,144 Cr, up from ₹2,529 Cr YoY. Consolidated PAT rose to ₹902 Cr from ₹545 Cr. Standalone PAT was ₹891 Cr. The company appointed Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel effective August 1, 2026.
The substantial increase in revenue and profits, along with key management appointments, are material events that will likely influence investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in both consolidated and standalone total income, PBT, and PAT, indicating strong financial performance.
Divi's Laboratories Limited announced its financial results for the quarter ended June 30, 2026, following a Board Meeting held on August 01, 2026. The company reported a consolidated total income of ₹3,144 crores, a significant increase from ₹2,529 crores in the corresponding quarter of the previous financial year. Consolidated Profit Before Tax (PBT) stood at ₹1,180 crores, up from ₹733 crores year-on-year, and consolidated Profit After Tax (PAT) was ₹902 crores, compared to ₹545 crores in the prior year's quarter. The company also reported a consolidated forex loss of ₹7 crores for the quarter.
On a standalone basis, Divi's Laboratories recorded a total income of ₹3,037 crores for the quarter ended June 30, 2026, with PBT at ₹1,165 crores and PAT at ₹891 crores. The standalone forex loss for the period was ₹7 crores.
In addition to the financial results, the Board approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. Mr. Prasad, General Manager (Engineering Purchase), has been with the company since 1994 and brings over 31 years of experience in pharmaceutical procurement and supply chain management. Mr. Rao, General Manager (Raw Materials Purchase), joined in 1995 and has over 30 years of experience in managing pharmaceutical procurement operations. The Board Meeting commenced at 10:15 Hrs and concluded at 11:20 Hrs on August 01, 2026.
What to do with a filing like this
Divi's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Divi's Laboratories Limited. Read the original for the full detail.